Storms Pharma
Sources: the KBO register on 19-11-2026; the National Bank, 2025 annual accounts filed on 03-07-2026; the Belgian Official Gazette, latest deed of 25-10-2021.
Grounds
the facts the verdict rests on, each with its source- Storms Pharma made a profit in every financial year since 2018.Annual accounts 2018 to 2025 page 2
- Equity stands at €1.0m, or 50.6% of the balance sheet total of €2.0m. That is more than 59% of the 7,187 companies in the financial services sector (NACE 64).Annual accounts 2025 page 2
- Cash fell from €24,582 to €14,370.Annual accounts 2024 and 2025 page 2
- Of the €1.0m of debt, €528,461 runs for more than a year.Annual accounts 2025, notes page 2
- The last five annual accounts came in on time. The 2025 accounts were filed 28 days before the end of the term.National Bank, filing of 03-07-2026 page 5
Representation
The sole director, , represents Storms Pharma alone.
Articles of association, Belgian Official Gazette of 25-10-2021, deed 21363056
Ownership
holds 999 shares. There is one other shareholder.
Deed of 20-10-2017
Financial situation
Annual accounts 2021 to 2025, as filed with the National Bank
Gross margin and net resultin €m
Equity and debtsin €m
Cashin €m
| Financial year | 2021 | 2022 | 2023 | 2024 | 2025 | Trend |
|---|---|---|---|---|---|---|
| Results | ||||||
| Gross margin | €59,613 | €57,330 | €63,711 | €62,102 | €77,174 | |
| Operating result | €57,473 | €56,007 | €61,826 | €60,442 | €75,627 | |
| Net result | €117,585 | €204,173 | €174,146 | €183,555 | €249,362 | |
| Balance sheet at the closing date | ||||||
| Equity | €480,053 | €669,227 | €823,373 | €778,197 | €1.0m | |
| Debts | €1.5m | €1.4m | €1.2m | €1.2m | €1.0m | |
| Debts due after more than one year | €1.3m | €1.2m | €908,916 | €794,374 | €528,461 | |
| Debts due within one year | €183,307 | €142,549 | €282,920 | €448,282 | €463,048 | |
| Cash | €3,540 | €16,833 | €19,828 | €24,582 | €14,370 | |
| Balance sheet total | €2.0m | €2.1m | €2.0m | €2.0m | €2.0m | |
| Ratios | ||||||
| Solvency | 23.7% | 32.6% | 40.7% | 38.4% | 50.6% | |
| Liquidity | 0.14 | 0.42 | 0.09 | 0.07 | 0.07 | |
Source: Annual accounts 2025, abbreviated format, filed on 03-07-2026 (2026-00253449); Annual accounts 2024, abbreviated format, filed on 01-07-2025 (2025-00229833); Annual accounts 2021 to 2023, filed from 25-07-2022 to 11-07-2024 (2022-20220059, 2023-00214085, 2024-00237784).
The operating result of 2025 is 25% higher than in 2024.
Debts fell by €244,391 in 2025.
The 2025 annual accounts state no amount of overdue tax or social security (RSZ) debts.
Board, signature and ownership
Position on 19-11-2026 according to the deeds in the Belgian Official Gazette and the annual accounts
Who represents the company
The sole director, , represents Storms Pharma alone.
Articles of association, Belgian Official Gazette of 25-10-2021, deed 21363056
Board
one director in officeOwnership and group
Shareholders
holds 999 shares. holds 1 share.
Deed of 20-10-2017
Board changes
changes role from manager to director.
Gazette, deed 21363056Holdings
Storms Pharma has 1 direct subsidiary (own 2025 accounts).
| Country | Company | Equity | Result | |
|---|---|---|---|---|
| Belgium 1 | ||||
| BE | 99.82% | €423,279 | result €234,765 | |
Source: List of holdings in its own 2025 accounts. Every holding stands with its own latest accounts.
Events and comparison
The latest events, newest first
Annual accounts 2025 filed, 28 days before the deadline.
NBB filingEquity above €1m. Equity rises from €778,197 to €1.0m.
FinancialAnnual accounts 2024 filed, 30 days before the deadline.
NBB filingAnnual accounts 2023 filed, 20 days before the deadline.
NBB filingRegistered in the Peppol Directory. Reachable for e-invoices through 0208:0683469918.
Annual accounts 2022 filed, 25 days before the deadline.
NBB filingEquity above €500,000. With a profit in every financial year since 2018, equity grows to €669,227.
FinancialAnnual accounts 2021 filed, 6 days before the deadline.
NBB filingchanges role from manager to director.
Gazette, deed 21363056Annual accounts 2020 filed, 15 days before the deadline.
NBB filingAnnual accounts 2019 filed, 31 days late.
NBB filingHighest result from 2018 to 2025. The operating result of €78,289 and the net result of €268,223 are both a record.
FinancialEquity above €200,000. With a profit in every financial year since 2018, equity grows to €343,301.
FinancialAnnual accounts 2018 filed, 16 days before the deadline.
NBB filingIn 2025, Storms Pharma had a higher net result than 78% of the 7,185 companies in the financial services sector (NACE 64).
Other findings
Peppol
Reachable for e-invoices since 24-11-2023, under 0208:0683469918.
Sanctions lists
Sources and method
Where each fact in this report comes from
| Source | What | Date | Reference |
|---|---|---|---|
| KBO register | Registration, legal situation, activity, establishment units | 19-11-2026 | KBO 0683.469.918 |
| National Bank of Belgium | Annual accounts 2025, abbreviated format | 03-07-2026 | 2026-00253449 |
| National Bank of Belgium | Annual accounts 2024, abbreviated format | 01-07-2025 | 2025-00229833 |
| National Bank of Belgium | Annual accounts 2021 to 2023 | 25-07-2022 to 11-07-2024 | 2022-20220059, 2023-00214085, 2024-00237784 |
| Belgian Official Gazette | Articles of association with the signing rule | 25-10-2021 | deed 21363056 |
| Peppol Directory | Registration for e-invoices | 24-11-2023 | 0208:0683469918 |
| Sanctions lists EU, UN, US (OFAC) and UK | Comparison of the name | 16-11-2026 | no match |
Method
Checked score. A number from 0 to 100. The bankruptcy probability sets the class, from Critical to Excellent; within the class, the comparison with sector peers on solvency, liquidity, profitability and growth counts for half.
Bankruptcy probability. The probability that the company goes bankrupt within 12 months, estimated from the KBO register, the annual accounts and the Gazette with the bankruptcy model of 2 October 2026, computed on 18-11-2026.
Credit. The credit is a tenth of equity, weighted by the score, and never more than a tenth of turnover. With negative equity there is no credit.
Payment terms. Supplier credit is the debt to suppliers divided by the year's purchases, times 365. Customer credit is the same for what customers still owe, against turnover.
Comparable companies. Companies of the same size, age, solvency and profitability at an earlier date, followed two years later in the KBO register and the Gazette.
The scores and ratios are Checked's own calculations, not a credit decision.